1. Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy
- Author
-
Alison M. Pack, Page B. Pennell, E. E. Moore, Jaqueline A. French, Jennifer Cavitt, Kimford J. Meador, Ryan C May, Sean Hwang, Patricia Penovich, Maria Sam, Naymee Velez-Ruiz, Elizabeth E. Gerard, Dominic Ippolito, and Laura A. Kalayjian
- Subjects
Adult ,Topiramate ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Population ,Zonisamide ,Lamotrigine ,Drug Prescriptions ,Article ,Young Adult ,03 medical and health sciences ,Behavioral Neuroscience ,Epilepsy ,0302 clinical medicine ,Pregnancy ,Seizures ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,education ,Oxcarbazepine ,Intelligence Tests ,Brain Diseases ,education.field_of_study ,business.industry ,Pregnancy Outcome ,Carbamazepine ,Middle Aged ,medicine.disease ,United States ,Neurology ,Anticonvulsants ,Drug Therapy, Combination ,Female ,Neurology (clinical) ,Levetiracetam ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
OBJECTIVE: We analyzed current prescribing patterns for antiepileptic drugs (AEDs) in pregnant women with epilepsy (PWWE) at 20 USA tertiary epilepsy centers. METHODS: The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study is an NIH-funded, prospective, observational, multi-center investigation of pregnancy outcomes for both mother and child, which enrolled women from December 2012 to January 2016. Inclusion criteria for PWWE included ages 14–45 years and up to 20 weeks gestational age. Exclusion criteria included history of psychogenic non-epilepstic spells, expected IQ
- Published
- 2018
- Full Text
- View/download PDF